121 related articles for article (PubMed ID: 27618777)
1. Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer.
Miao R; Wu Y; Zhang H; Zhou H; Sun X; Csizmadia E; He L; Zhao Y; Jiang C; Miksad RA; Ghaziani T; Robson SC; Zhao H
Sci Rep; 2016 Sep; 6():33121. PubMed ID: 27618777
[TBL] [Abstract][Full Text] [Related]
2. TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells.
Liu X; Liao W; Yuan Q; Ou Y; Huang J
Oncotarget; 2015 Oct; 6(33):34309-20. PubMed ID: 26418879
[TBL] [Abstract][Full Text] [Related]
3. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21.
Zhang H; Yao W; Zhang M; Lu Y; Tang J; Jiang M; Mou X; You G; Liang X
Biochem Biophys Res Commun; 2021 Apr; 550():84-91. PubMed ID: 33689884
[TBL] [Abstract][Full Text] [Related]
4. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
Liang XD; Dai YC; Li ZY; Gan MF; Zhang SR; Yin-Pan ; Lu HS; Cao XQ; Zheng BJ; Bao LF; Wang DD; Zhang LM; Ma SL
PLoS One; 2014; 9(6):e97739. PubMed ID: 24905462
[TBL] [Abstract][Full Text] [Related]
5. TTK Inhibitors as a Targeted Therapy for
Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of
Tsai YM; Wu KL; Chang YY; Hung JY; Chang WA; Chang CY; Jian SF; Tsai PH; Huang YC; Chong IW; Hsu YL
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121246
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
9. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Maire V; Baldeyron C; Richardson M; Tesson B; Vincent-Salomon A; Gravier E; Marty-Prouvost B; De Koning L; Rigaill G; Dumont A; Gentien D; Barillot E; Roman-Roman S; Depil S; Cruzalegui F; Pierré A; Tucker GC; Dubois T
PLoS One; 2013; 8(5):e63712. PubMed ID: 23700430
[TBL] [Abstract][Full Text] [Related]
10. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progression.
Kronschnabl P; Grünweller A; Hartmann RK; Aigner A; Weirauch U
Int J Oncol; 2020 Feb; 56(2):448-459. PubMed ID: 31894300
[TBL] [Abstract][Full Text] [Related]
12. Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
Chen S; Wang J; Wang L; Peng H; Xiao L; Li C; Lin D; Yang K
Exp Cell Res; 2019 Dec; 385(1):111669. PubMed ID: 31605696
[TBL] [Abstract][Full Text] [Related]
13. Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer.
Miao Y; Konno Y; Wang B; Zhu L; Zhai T; Ihira K; Kobayashi N; Watari H; Jin X; Yue J; Dong P; Fang M
J Transl Med; 2023 Feb; 21(1):151. PubMed ID: 36829176
[TBL] [Abstract][Full Text] [Related]
14. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.
Lee N; Kwon JH; Kim YB; Kim SH; Park SJ; Xu W; Jung HY; Kim KT; Wang HJ; Choi KY
Oncotarget; 2015 Oct; 6(30):30130-48. PubMed ID: 26375549
[TBL] [Abstract][Full Text] [Related]
15. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.
Stratford JK; Yan F; Hill RA; Major MB; Graves LM; Der CJ; Yeh JJ
PLoS One; 2017; 12(4):e0174863. PubMed ID: 28380042
[TBL] [Abstract][Full Text] [Related]
16. TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination.
Chandler BC; Moubadder L; Ritter CL; Liu M; Cameron M; Wilder-Romans K; Zhang A; Pesch AM; Michmerhuizen AR; Hirsh N; Androsiglio M; Ward T; Olsen E; Niknafs YS; Merajver S; Thomas DG; Brown PH; Lawrence TS; Nyati S; Pierce LJ; Chinnaiyan A; Speers C
J Clin Invest; 2020 Feb; 130(2):958-973. PubMed ID: 31961339
[TBL] [Abstract][Full Text] [Related]
17. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis underlying resistance to Mps1/TTK inhibitors.
Koch A; Maia A; Janssen A; Medema RH
Oncogene; 2016 May; 35(19):2518-28. PubMed ID: 26364596
[TBL] [Abstract][Full Text] [Related]
19. A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer.
Chen X; Yu C; Gao J; Zhu H; Cui B; Zhang T; Zhou Y; Liu Q; He H; Xiao R; Huang R; Xie H; Gao D; Zhou H
Theranostics; 2018; 8(9):2348-2360. PubMed ID: 29721084
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G
Zhu D; Xu S; Deyanat-Yazdi G; Peng SX; Barnes LA; Narla RK; Tran T; Mikolon D; Ning Y; Shi T; Jiang N; Raymon HK; Riggs JR; Boylan JF
Mol Cancer Ther; 2018 Aug; 17(8):1727-1738. PubMed ID: 29866747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
